α-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes

Chemical Research in Toxicology

Volumn 16, Issue 9, 2003, Pages 1138-1144

  Kim, Sung Yeon ^a   Suzuki, Naomi ^a   Laxmi, Y R Santosh ^a   Rieger, Robert ^a   Shibutani, Shinya ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYTAMOXIFEN; ALPHA HYDROXYTOREMIFENE; CYTOCHROME P450 3A; DRUG METABOLITE; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; DNA ADDUCT; DRUG METABOLISM; DRUG STRUCTURE; ENDOMETRIUM CANCER; ENZYME ACTIVITY; GENOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METABOLITE; NONHUMAN; RAT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DEOXYGUANINE NUCLEOTIDES; FEMALE; HUMANS; HYDROXYLATION; MASS SPECTROMETRY; NADPH OXIDASE; RATS; TAMOXIFEN; TOREMIFENE;

STAPHYLOCOCCUS PHAGE 3A; TOR;

EID: 0141513744     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx0300131     Document Type: Article

References (69)

1. Jordan, V. C. (1995) Tamoxifen for breast cancer prevention. Proc. Soc. Exp. Biol. Med. 208, 144-149.
2. Osborne, C. K. (1998) Tamoxifen in the treatment of breast cancer. New Engl. J. Med. 339, 1609-1617.
3. Fischer, B., Costantino, J. P., Wickerham, L., Redmond, C. K., Kavanah, M., Cronin, W. M., Botel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., Wormark, N., et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90, 1371-1388.
4. Killackey, M., Hakes, T. B., and Pierce, V. K. (1985) Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat. Rep. 69, 237-238.
5. Seoud, M. A.-F., Johnson, J., and Weed, J. C. (1993) Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet. Gynecol. 82, 165-169.
6. Fischer, B., Costantino, J. P., Redmond, C. K., Fisher, E. R., Wickerham, D. L., and Cronin, W. M. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP, B-14). J. Natl. Cancer Inst. 86, 527-537.
7. Van Leeuwen, F. E., Benraadt, J., Coebergh, J. W. W., Kiemeney, L. A. L. M., Diepenhorst, F. W., van den Belt-Dusebout, A. W., and van Tinteren, H. (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343, 448-452.
8. Clarke, M., Cillins, R., Davies, C., Godwin, J., Gray, R., and Peto, R. (1998) Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351, 1451-1467.
9. Bernstein, L., Deapen, D., Cerhan, J. R., Schwartz, S. M., Liff, J., McGann-Maloney, E., Perlman, J. A., and Ford, L. (1999) Tamoxifen therapy for breast cancer and endometrial cancer risk. J. Natl. Cancer Inst. 91, 1654-1662.
10. Williams, G. M., Iatropoulos, M. J., Djordjevic, M. V., and Kaltenberg, O. P. (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14, 315-317.
11. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J., and Orton, T. (1993) Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res. 53, 3919-3924.
12. Hard, G. C., Iatropoulos, M. J., Jordan, K., Radi, L., Kaltenberg, O. P., Imondi, A. R., and Williams, G. M. (1993) Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res. 53, 4534-4541.
13. Han, X., and Liehr, J. G. (1992) Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res. 52, 1360-1363.
14. White, I. N. H., de Matteis, F., Davies, A., Smith, L. L., Crofton-Sleigh, C., Venitt, S., Hewer, A., and Phillips, D. H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57B1/6 mice and in human MCL-5 cells. Carcinogenesis 13, 2197-2203.
15. Osborne, M. R., Hewer, A., Hardcastle, I. R., Carmichael, P. L., and Phillips, D. H. (1996) Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res. 56, 66-71.
16. 32P-post-labeled DNA adducts by the development of a novel automated on-line solid-phase extraction HPLC method. Carcinogenesis 19, 1061-1069.
17. Divi, R. L., Dragan, Y. P., Pitot, H. C., and Poirier, M. C. (2001) Immunohistochemical localization and semiquantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen. Carcinogenesis 22, 1693-1699.
18. Pathak, D. N., and Bodell, W. J. (1994) DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis 15, 529-532.
19. Pathak, D. N., Pongracz, K., and Bodell, W. J. (1995) Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts: comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Carcinogenesis 16, 11-15.
20. Hemminki, K., Widlak, P., and Hou, S. M. (1995) DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis 16, 1661-1664.
21. IARC (1996) Some pharmaceutical drugs. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 66, IARC, Lyon, France.
22. Potter, G. A., McCague, R., and Jarman, M. (1994) A mechanism hypothesis for DNA adduct formation by tamoxifen hepatic oxidative metabolism. Carcinogenesis 15, 439-442.
23. 5-ethyl]-tamoxifen implicates α-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis 15, 1487-1492.
24. Phillips, D. H., Carmichael, P. L., Hewer, A., Cole, K. J., and Poon, G. K. (1994) α-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res. 54, 5518-5522.
25. 5ethtyl]tamoxifen. Carcinogenesis 16, 683-688.
26. Poon, G. K., Walter, B., Lonning, P. E., Horton, M. N., and McCague, R. (1995) Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab. Dispos. 23, 377-382.
27. Nelson, D. R., Kamataki, T., Waxman, D. J., Guengerich, F. P., Estabrook, R. W., Feyereisen, R., Gonzalez, F. J., Coon, M. J., Gunsalus, I. C., Gotoh, O., Okuda, K., and Nebert, D. W. (1993) The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 12, 1-51.
28. Mani, C., and Kupfer, D. (1991) Cytochrome P-450-mediated activation and irreversible binding of the antioestrogen tamoxifen to proteins in rats and human liver: possible involvement of flavin-containing mono-oxygenases in tamoxifen activation. Cancer Res. 51, 6052-6058.
29. Lim, C. K., Yuan, Z. X., Lamb, J. H., White, I. N., De Matteis, F., and Smith, L. L. (1994) A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis 15, 589-593.
30. Hengstler, J. G., Van der Burg, B., Steinberg, P., and Oesch, F. (1999) Interspecies differences in cancer susceptibility and toxicity. Drug Metab. Rev. 31, 917-970.
31. Furr, B. J. A., and Jordan, V. C. (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther. 25, 127-205.
32. Jacolot, F., Simon, I., Dreano, Y., Beaune, P., Riche, C., and Berthou, F. (1991) Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol. 41, 1911-1919.
33. Mani, C., Gelboin, H. V., Park, S. S., Pearce, R., Parkinson, A., and Kupfer, D. (1993) Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug. Metab. Dispos. 21, 645-656.
34. Crewe, H. K., Ellis, S. W., Lennard, M. S., and Tucker, G. T. (1997) Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. 53, 171-178.
35. Dehal, S. S., and Kupfer, D. (1997) CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res. 57, 3402-3406.
36. Boocock, D. J., Maggs, J. L., White, I. N., and Park, B. K. (1999) α-Hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: identification and quantification in vivo and in vitro. Carcinogenesis 20, 153-160.
37. Sridar, C., Kent, U. M., Notley, L. M., Gillam, E. M., and Hollenberg, P. F. (2002) Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J. Pharmacol. Exp. Ther. 301, 945-952.
38. Boocock, D. J., Brown, K., Gibbs, A. H., Sanchez, E., Turteltaub, K. W., and White, I. N. H. (2002) Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 23, 1897-1901.
39. Shibutani, S., Dasaradhi, L., Terashima, I., Banoglu, E., and Duffel, M. W. (1998) α-Hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res. 58, 647-653.
40. Shibutani, S., Shaw, P., Suzuki, N., Dasaradhi, L., Duffel, M. W., and Terashima, I. (1998) Sulfation of α-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen DNA adducts. Carcinogenesis 19, 2007-2011.
41. Dasaradhi, L., and Shibutani, S. (1997) Identification of tamoxifen-DNA adducts formed by α-sulfate tamoxifen and α-acetoxy-tamoxifen. Chem. Res. Toxicol. 10, 189-196.
42. Osborne, M. R., Hardcastle, I. R., and Phillips, D. H. (1997) Minor products of reaction of DNA with α-acetoxytamoxifen. Carcinogenesis 18, 539-543.
43. Rajaniemi, H., Rasanen, I., Koivisto, P., Peltonen, K., and Hemminki, K. (1999) Identification of the major tamoxifen-DNA adducts in rats liver by mass spectroscopy. Carcinogenesis 20, 305-309.
44. 2-deoxyguanosinyl)tamoxifen N-oxide. Carcinogenesis 21, 1737-1744.
45. Umemoto, A., Komaki, K., Monden, Y., Suwa, M., Kanno, Y., Kitagawa, M., Suzuki, M., Lin, C.-X., Ueyama, Y., Momen, M. A., Ravindernath, A., and Shibutani, S. (2001) Identification and quantification of tamoxifen-DNA adducts in the liver of rats and mice. Chem. Res. Toxicol. 14, 1006-1013.
46. Shibutani, S., Suzuki, N., Terashima, I., Sugarman, S. M., Grollman, A. P., and Pearl, M. L. (1999) Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem. Res. Toxicol. 12, 646-653.
47. Shibutani, S., Ravindernath, A., Suzuki, N., Terashima, I., Sugarman, S. M., Grollman, A. P., and Pearl, M. L. (2000) Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 21, 1461-1467.
48. Marques, M. M., and Beland, F. A. (1997) Identification of tamoxifen-DNA adducts formed by 4-hydroxytamoxifen quinone methide. Carcinogenesis 18, 1949-1954.
49. Beland, F. A., McDaniel, L. P., and Marques, M. M. (1999) Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo. Carcinogenesis 20, 471-477.
50. Davies, R., Oreffo, V. I. C., Martin, E. A., Festing, M. F. W., White, I. N. H., Smith, L. L., and Styles, J. A. (1997) Tamoxifen causes gene mutations in the livers of lamda/lacI transgenic rats. Cancer Res. 57, 1288-1293.
51. 2-deoxyguanosinyl)tamoxifen. Biochemistry 56, 13010-13017.
52. 2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res. 59, 2091-2095.
53. Shibutani, S., Reardon, J. T., Suzuki, N., and Sancar, A. (2000) Excision of tamoxifen-DNA adducts by the human nucleotide excision repair system. Cancer Res. 60, 2607-2610.
54. Berthou, F., Dreano, Y., Belloc, C., Kangas, L., Gautier, J.-C., and Beaune, P. (1994) Involvement of cytochrome P450 3A enzyme family in the major metabolite pathways of toremifene in human liver microsomes. Biochem. Pharmacol. 47, 1883-1895.
55. Jones, R. M., and Lim, C. K. (2002) Toremifene metabolism in rat, mouse and human liver microsomes: Identification of α-hydroxytoremifene by LC-MS. Biomed. Chromatogr. 16, 361-363.
56. Anttila, M., Valavaara, R., Kivinen, S., and Mäenpää, J. (1990) Pharmacokinetics of toremifene. J. Steroid Biochem. 36, 249-251.
57. Sipilä, H., Kangas, L., Vuorilehto, L., Kalapudas, A., Eloranta, M., Södervall, M., Toivola, R., and Anttila, M. (1990) Metabolism of toremifene in the rat. J. Steroid Biochem. 36, 211-215.
58. Watanabe, N., Koyama, M., Yamashita, K., and Tominaga, T. (1996) Metabolism of toremifene in the rat. Antibiot. Chemother. (Japanese) 12, 287-296.
59. Li, D., Dragan, Y., Jordan, V. C., Wang, M., and Pitot, H. C. (1997) Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Cancer Res. 57, 1438-1441.
60. Foster, A. B., Jarman, M., Leung, O. T., McCague, R., Leclercq, G., and Devleeschouwer, N. (1985) Hydroxy derivatives of tamoxifen. J. Med. Chem. 28, 1491-1497.
61. Shibutani, S., Ravindernath, A., Terashima, I., Suzuki, N., Santosh, L. Y. R., Kanno, Y., Suzuki, M., Apak, T. I., Sheng, J. J., and Duffel, M. W. (2001) Mechanism of lower genotoxicity of toremifene compared with tamoxifen. Cancer Res. 61, 3925-3931.
62. Gauthier, S., Mailhot, J., and Labrie, F. (1996) New high stereoselective synthesis of (Z)-4-hydroxytamoxifen and (Z)-4hydroxytoremifene via McMurry reaction. J. Org. Chem. 61, 3890-3893.
63. Gamboa da Costa, G., McDaniel-Hamilton, L. P., Heflich, R. H., Marques, M. M., and Beland, F. A. (2001) DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives. Carcinogenesis 22, 1307-1315.
64. Kitagawa, M., Ravindernath, A., Suzuki, N., Rieger, R., Terashima, I., Umemoto, A., and Shibutani, S. (2000) Identification of tamoxifen-DNA adducts induced by α-acetoxy-N-desmethyltamoxifen. Chem. Res. Toxicol. 13, 761-769.
65. Parr, I. B., McCague, R., Leclercq, G., and Stoessel, S. (1987) Metabolism of tamoxifen by isolated rat hepatocytes. Identification of 1-[4-(2-hydroxyethoxy)phenyl]-1-(4-hydroxyphenyl)-2phenyl-1-butene and the dependence of N-oxidation on oxygen availability. Biochem. Pharmacol. 36, 513-519.
66. Crewe, H. K., Notley, L. M., Wunsch, R. M., Lennard, M. S., and Gillam, E. M. (2002) Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos. 30, 869-874.
67. Hukkanen, J., Mantyla, M., Kangas, L., Wirta, P., Hakkola, J., Paakki, P., Evisalmi, S., Pelkonen, O., and Raunio, H. (1998) Expression of cytochrome P450 genes encoding enzymes active in the metabolism of tamoxifen in human uterine endometrium. Pharmacol. Toxicol. 82, 93-97.
68. Kasahara, T., Hashiba, M., Harada, T., and Degawa, M. (2002) Change in the gene expression of hepatic tamoxifen-metabolizing enzymes during the process of tamoxifen-induced hepatocarcinogenesis in female rats. Carcinogenesis 23, 491-498.
69. Buzdar, A., and Hortobagyi, G. N. (1998) Tamoxifen and toremifene in breast cancer comparison of safety and efficacy. J. Clin. Oncol. 16, 348-353.